Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Characterization of angiotensin II antagonism displayed by KR-31081, a novel nonpeptide AT1 receptor antagonist

안지오텐신 수용체 길항제 KR-31081의 특성에 관한 연구

  • Lee, Sung-Hou (Department of Biomedical Technology, Sangmyung University)
  • 이승호 (상명대학교 공과대학 의생명공학과)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The pharmacological profile of KR-31081, a nonpeptide $AT_1$ selective angiotensin receptor antagonist, was investigated by receptor binding studies, functional in vitro assays with rabbit aorta. KR-31081 inhibited the specific binding of $[^{125}I]\;[Sar^1,\;Ile^8]$-angiotensin II to human recombinant $AT_1$ receptor with an 8.6-fold greater potency than losartan ($IC_{50}$: 1.43 and 12.3 nM, respectively), but it did not inhibit the binding of [$^{125}I$] CGP 42112A to human recombinant $AT_2$ receptor ($IC_{50}$: higher than $10{\mu}M$ for both). The Hill coefficient for the competition curve of KR-31081 against $AT_1$ receptor was not significantly different from unity (0.99). Scatchard analysis showed that KR-31081 interacted with human recombinant $AT_1$ receptor in a competitive manner, as with losartan. In functional studies with rabbit aorta, KR-31081 competitively inhibited the contractile response to angiotensin II ($pK_B$ values: 8.66) with 20-70% decrease in the maximum contractile responses, unlike losartan that showed competitive antagonism without any change in the maximum contractile responses to angiotensin II ($pA_2$ values: 7.59). These results suggest that KR-31081 is a highly potent $AT_1$ selective angiotensin II receptor antagonist with a mode of insurmountable antagonism to be developed as the exploratory potential of this compound.

비펩타이드성 안지오텐신 수용체 길항제로 새롭게 개발된 KR-31081은 재조합 수용체 결합실험에서 기존 의약인 로사탄에 비하여 8.6배 이상의 월등한 효과를 나타내었으며, 기능성 혈관실험에서도 대조물질인 로자탄보다 혈관수축 억제효과가 10배 이상 탁월하였다. 이러한 KR-31081의 특징들은 제 1형의 안지오텐신 수용체에 특이적으로 나타났으며 제 2형의 안지오텐신 수용체에 대한 수용체 결합친화력이 발견되지 않았다. 기능성 혈관실험에서는 KR-31081이 안지오텐신에 의한 혈관수축 효과를 경쟁적으로 저하시켰지만 표준물질인 로자탄과는 달리 농도가 증가함에 따라 혈관자체의 최고 수축효과의 감소가 관찰되었다. 안지오텐신 수용체에 선택적으로 작용하는 것으로 나타난 KR-31081은 고혈압 및 혈관질환에 대한 연구 및 진단에 활용될 수 있을 것이라고 판단된다.

Keywords

References

  1. M. B. Vallotton, "The renin - angiotensin system", Trends Pharmacol Sci, 8, pp. 69-74, 1987. https://doi.org/10.1016/0165-6147(87)90013-7
  2. P. S. Sever, A. H. Gradman, and M. Azizi, "Managing cardiovascular and renal risk: the potential of direct renin inhibition", J Renin Angiotensin Aldosterone Syst, 10, pp. 65-76, 2009. https://doi.org/10.1177/1470320309104662
  3. R. J. Cody, "Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure", J Cardiovasc Pharmacol, 8 Suppl 1, pp. S58-65, 1986.
  4. G. H. Williams, "Converting-enzyme inhibitors in the treatment of hypertension", N Engl J Med, 319, pp. 1517-25, 1988. https://doi.org/10.1056/NEJM198812083192305
  5. J. R. Roberts, and R. C. Wuerz, "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema", Ann Emerg Med, 20, pp. 555-8, 1991. https://doi.org/10.1016/S0196-0644(05)81616-6
  6. D. M. Coulter, and I. R. Edwards, "Cough associated with captopril and enalapril", Br Med J (Clin Res Ed), 294, pp. 1521-3, 1987. https://doi.org/10.1136/bmj.294.6586.1521
  7. W. Wienen, A. B. Mauz, J. C. Van Meel, and M. Entzeroth, "Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies", Mol Pharmacol, 41, pp. 1081-8, 1992.
  8. P. B. Timmermans, and R. D. Smith, "Angiotensin II receptor subtypes: selective antagonists and functional correlates", Eur Heart J, 15 Suppl D, pp. 79-87, 1994. https://doi.org/10.1093/eurheartj/15.suppl_D.79
  9. P. C. Wong, W. A. Price, Jr., A. T. Chiu, J. V. Duncia, D. J. Carini, R. R. Wexler, A. L. Johnson, and P. B. Timmermans, "In vivo pharmacology of DuP 753", Am J Hypertens, 4, pp. 288S-298S, 1991. https://doi.org/10.1093/ajh/4.3.288
  10. P. C. Wong, W. A. Price, A. T. Chiu, J. V. Duncia, D. J. Carini, R. R. Wexler, A. L. Johnson, and P. B. Timmermans, "Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent", J Pharmacol Exp Ther, 252, pp. 726-32, 1990.
  11. P. C. Wong, S. D. Hart, J. V. Duncia, and P. B. Timmermans, "Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs", Eur J Pharmacol, 202, pp. 323-30, 1991. https://doi.org/10.1016/0014-2999(91)90274-T
  12. J. M. Mallion, and A. I. Goldberg, "Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension", Blood Press Suppl, 2, pp. 82-6, 1996.
  13. B. Dahlof, S. E. Keller, L. Makris, A. I. Goldberg, C. S. Sweet, and N. Y. Lim, "Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension", Am J Hypertens, 8, pp. 578-83, 1995. https://doi.org/10.1016/0895-7061(95)00081-Y
  14. K. Dickstein, S. Gottlieb, E. Fleck, J. Kostis, B. Levine, M. DeKock, and T. LeJemtel, "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure", J Hypertens Suppl, 12, pp. S31-5, 1994.
  15. W. B. Mathews, S. E. Yoo, S. H. Lee, U. Scheffel, P. A. Rauseo, T. G. Zober, G. Gocco, K. Sandberg, H. T. Ravert, R. F. Dannals, and Z. Szabo, "A novel radioligand for imaging the AT1 angiotensin receptor with PET", Nucl Med Biol, 31, pp. 571-4, 2004. https://doi.org/10.1016/j.nucmedbio.2003.10.014
  16. J. Xia, E. Seckin, Y. Xiang, M. Vranesic, W. B. Mathews, K. Hong, D. A. Bluemke, L. O. Lerman, and Z. Szabo, "Positron-emission tomography imaging of the angiotensin II subtype 1 receptor in swine renal artery stenosis", Hypertension, 51, pp. 466-73, 2008. https://doi.org/10.1161/HYPERTENSIONAHA.107.102715
  17. T. G. Zober, W. B. Mathews, E. Seckin, S. E. Yoo, J. Hilton, J. Xia, K. Sandberg, H. T. Ravert, R. F. Dannals, and Z. Szabo, "PET Imaging of the AT1 receptor with [11C]KR31173", Nucl Med Biol, 33, pp. 5-13, 2006. https://doi.org/10.1016/j.nucmedbio.2005.08.005
  18. Y. Cheng, and W. H. Prusoff, "Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction", Biochem Pharmacol, 22, pp. 3099-108, 1973. https://doi.org/10.1016/0006-2952(73)90196-2
  19. W. Wienen, N. Hauel, J. C. Van Meel, B. Narr, U. Ries, and M. Entzeroth, "Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277", Br J Pharmacol, 110, pp. 245-52, 1993. https://doi.org/10.1111/j.1476-5381.1993.tb13800.x
  20. A. Hilditch, A. A. Hunt, A. Travers, J. Polley, G. M. Drew, D. Middlemiss, D. B. Judd, B. C. Ross, and M. J. Robertson, "Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist", J Pharmacol Exp Ther, 272, pp. 750-7, 1995.
  21. R. L. Panek, G. H. Lu, R. W. Overhiser, T. C. Major, J. C. Hodges, and D. G. Taylor, "Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism", J Pharmacol Exp Ther, 273, pp. 753-61, 1995.
  22. R. A. Bond, A. G. Ornstein, and D. E. Clarke, "Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation", J Pharmacol Exp Ther, 249, pp. 401-10, 1989.